| Detection of cancer DNA in plasma of patients with early-stage breast cancer JA Beaver, D Jelovac, S Balukrishna, RL Cochran, S Croessmann, ... Clinical cancer research 20 (10), 2643-2650, 2014 | 430 | 2014 |
| ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients D Chu, C Paoletti, C Gersch, DA VanDenBerg, DJ Zabransky, ... Clinical cancer research 22 (4), 993-999, 2016 | 184 | 2016 |
| Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models A Bahreini, Z Li, P Wang, KM Levine, N Tasdemir, L Cao, HM Weir, ... Breast Cancer Research 19, 1-10, 2017 | 141 | 2017 |
| Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage OA Negrete, D Chu, HC Aguilar, B Lee Journal of virology 81 (19), 10804-10814, 2007 | 118 | 2007 |
| Ki-67 is required for maintenance of cancer stem cells but not cell proliferation J Cidado, HY Wong, DM Rosen, A Cimino-Mathews, JP Garay, ... Oncotarget 7 (5), 6281, 2016 | 104 | 2016 |
| Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms C Paoletti, AK Cani, JM Larios, DH Hovelson, K Aung, EP Darga, ... Cancer research 78 (4), 1110-1122, 2018 | 102 | 2018 |
| Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA PV Toro, B Erlanger, JA Beaver, RL Cochran, DA VanDenBerg, E Yakim, ... Clinical biochemistry 48 (15), 993-998, 2015 | 97 | 2015 |
| HER2 missense mutations have distinct effects on oncogenic signaling and migration DJ Zabransky, CL Yankaskas, RL Cochran, HY Wong, S Croessmann, ... Proceedings of the National Academy of Sciences 112 (45), E6205-E6214, 2015 | 92 | 2015 |
| A mechanistic study of tumor-targeted corrole toxicity JY Hwang, J Lubow, D Chu, J Ma, H Agadjanian, J Sims, HB Gray, ... Molecular pharmaceutics 8 (6), 2233-2243, 2011 | 78 | 2011 |
| Cysteines in the stalk of the Nipah virus G glycoprotein are located in a distinct subdomain critical for fusion activation D Maar, B Harmon, D Chu, B Schulz, HC Aguilar, B Lee, OA Negrete Journal of virology 86 (12), 6632-6642, 2012 | 73 | 2012 |
| Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA M Hayashi, D Chu, CF Meyer, NJ Llosa, G McCarty, CD Morris, AS Levin, ... Cancer 122 (19), 3015-3023, 2016 | 72 | 2016 |
| Individualized molecular analyses guide efforts (IMAGE): a prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer HA Parsons, JA Beaver, A Cimino-Mathews, SM Ali, J Axilbund, D Chu, ... Clinical Cancer Research 23 (2), 379-386, 2017 | 69 | 2017 |
| Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity JY Hwang, DJ Lubow, D Chu, J Sims, F Alonso-Valenteen, HB Gray, ... Journal of controlled release 163 (3), 368-373, 2012 | 61 | 2012 |
| Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors Y Zhao, MJ Laws, VS Guillen, Y Ziegler, J Min, A Sharma, SH Kim, D Chu, ... Cancer research 77 (20), 5602-5613, 2017 | 58 | 2017 |
| Liquid biopsy: unlocking the potentials of cell-free DNA D Chu, BH Park Virchows Archiv 471, 147-154, 2017 | 57 | 2017 |
| Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer S Torquato, A Pallavajjala, A Goldstein, P Valda Toro, JL Silberstein, ... JCO precision oncology 3, 1-14, 2019 | 55 | 2019 |
| Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation WB Dalton, E Helmenstine, N Walsh, LP Gondek, DS Kelkar, A Read, ... The Journal of clinical investigation 129 (11), 4708-4723, 2019 | 54 | 2019 |
| Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells Z Li, KM Levine, A Bahreini, P Wang, D Chu, BH Park, S Oesterreich, ... Endocrinology 159 (1), 285-296, 2018 | 43 | 2018 |
| TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer HY Wong, GM Wang, S Croessmann, DJ Zabransky, D Chu, JP Garay, ... Oncotarget 6 (42), 44927, 2015 | 43 | 2015 |
| Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles JY Hwang, J Park, BJ Kang, DJ Lubow, D Chu, DL Farkas, KK Shung, ... PLoS One 7 (4), e34463, 2012 | 39 | 2012 |
Ben Ho ParkVanderbilt University Medical Center, Johns Hopkins University, University of PennsylvaniaVerified email at jhmi.edu
